{"id":76683,"date":"2026-08-26T13:07:00","date_gmt":"2026-08-26T05:07:00","guid":{"rendered":"https:\/\/flcube.com\/?p=76683"},"modified":"2026-08-26T13:07:01","modified_gmt":"2026-08-26T05:07:01","slug":"fda-approves-jjs-imaavy-for-warm-autoimmune-hemolytic-anemia-marking-second-indication-for-nipocalimab","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76683","title":{"rendered":"FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab"},"content":{"rendered":"\n

Johnson & Johnson (J&J, NYSE: JNJ<\/a>)<\/strong> announced that the US FDA<\/strong> has approved the second indication<\/strong> for IMAAVY (nipocalimab)<\/strong> \u2014 for the treatment of warm autoimmune hemolytic anemia (wAIHA)<\/strong> in adults and pediatric patients 12 years of age and older who are currently or previously treated with corticosteroids. The approval extends the franchise of J&J’s FcRn\u2011targeting franchise beyond its 2025 launch indication and into a rare, life\u2011threatening hematologic disease with few durable treatment options.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>US FDA<\/td><\/tr>
Approval Date<\/strong><\/td>24 Aug 2026<\/td><\/tr>
Product<\/strong><\/td>IMAAVY (nipocalimab)<\/td><\/tr>
Indication<\/strong><\/td>Warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients \u226512 years, currently or previously treated with corticosteroids<\/td><\/tr>
Significance<\/strong><\/td>Second approved indication for IMAAVY in the US<\/td><\/tr>
First Approval<\/strong><\/td>April 2025 \u2013 generalized myasthenia gravis (gMG), AChR or MuSK antibody\u2011positive, adults and pediatric patients \u226512 years<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n